Table of contents
- Trial overview
- Who can participate
- Treatment comparison in the study
- What is measured in the trial
- Trial phase and size
- What this means for patients
Trial overview
The listed study, TOXSIALO-TRIAL, looked at treatment for drooling in children with cerebral palsy and pathological drooling.[1]
It compared a scopolamine patch called Scopoderm with injections of botulinum toxin A into the salivary glands, both used with standardized rehabilitation guidance.[1]
The study was completed and included 132 participants.[1]
Who can participate
This trial focused on children who were 4 years old or older and had cerebral palsy with pathological drooling.[1]
Pathological drooling means drooling that is more than usual and causes problems in daily life.[1]
Treatment comparison in the study
The study compared two treatment approaches: a cutaneous scopolamine patch and an intraglandular injection of botulinum toxin A into the salivary glands.[1]
Cutaneous use means the treatment is applied through the skin, while intraglandular use means it is given directly into a gland.[1]
Both groups also received standardized rehabilitation guidance, which means planned support that was part of the study for all participants.[1]
What is measured in the trial
The main endpoint was the change in the degree and impact of drooling from the start of treatment to 15 months later.[1]
This was measured with the DIS scale, which is a rating tool for drooling severity and its effect on daily life.[1]
Trial phase and size
This was a Phase 3 study, which means it tested the treatments in a larger group to compare how well they worked.[1]
The enrollment was 132, so 132 people were included in the trial.[1]
What this means for patients
For families, this trial is important because it focused on a common and difficult problem in cerebral palsy: drooling that affects comfort and daily activities.[1]
The study was designed to see which treatment approach gave better long-term results over 15 months.[1]
Because the trial compared two active treatments, it was aimed at finding practical options for children who need help with drooling.[1]
